NCT07866326|Recruiting
Loading search results
Sponsor study identifier
observational
120
1 country
1
Study Start
July 31, 2026
Actual (reported)Primary Completion
July 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study aims to investigate the prevalence of adrenal insufficiency in rheumatoid arthritis (RA) patients receiving low-dose corticosteroid therapy and to identify the factors influencing adrenal insufficiency. To this end, the researchers plan to conduct a study comparing the prevalence of adrenal insufficiency and associated factors among RA patients-who are currently receiving low-dose corticosteroid therapy during outpatient follow-up and have consented to participate-by categorizing them into three groups based on the duration of treatment: short (3 weeks-3 months), medium (3-12 months), and long (\>12 months).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 31, 2026
Actual (reported)October 1, 2026
Actual (reported)October 8, 2026
Actual (reported)July 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
prevalence of adrenal insufficiency
The assessment of adrenal insufficiency is conducted in two stages: the morning cortisol level is measured in the first stage, and the ACTH stimulation test is administered to the relevant participants in the second stage.
through study completion, an average of 1 year
DAS-28
Disease activity score for rheumatoid arthritis
through study completion, an average of 1 year
HAQ
Health Assessment Questionnaires
through study completion, an average of 1 year
low-duration corticosteroid
medium-duration corticosteroid
long-duration corticosteroid
ACTH stimulation test with 250 micrograms tetracosactide acetate if plasma cortisole is below 10 mcg/dl
morning fasting plasma cortisol
The study population will be selected from RA patients followed at the Rheumatology Clinic of Bursa Yuksek Ihtisas Training and Research Hospital.
SBU Bursa Yüksek İhtisas EAH
Bursa, Yıldırım, Turkey (Türkiye)
First Submitted
October 1, 2026
First Posted
October 8, 2026
Study Start
July 31, 2026
Actual (reported)Primary Completion
July 30, 2027
EstimatedScreening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)
RAPİD-3
Routine Assessment of Patient Index Data 3
through study completion, an average of 1 year
PASI
Psoriasis Area Severity Index
through study completion, an average of 1 year
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 8, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: